文献速递白血病

维莫非尼治疗儿童难治性多系统朗格汉斯细胞组织细胞增生症:国际观察性研究

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
PubMed 文献 · J Clin Oncol · 2019-09-12

8周时38例完全缓解、16例部分缓解,疾病活动评分中位数从7降至0(P < .001);皮肤皮疹最常见(74%),未观察继发皮肤癌。停药后30例中24例复发,无维持治疗可清除BRAFV600E克隆。

要点

  • 维莫非尼对难治性BRAFV600E阳性儿童LCH安全有效,8周应答率高。
  • 皮肤皮疹最常见(74%),未观察继发皮肤癌。
  • 停药后复发常见,BRAFV600E等位基因负荷与复发风险相关。

核心结论

  • 维莫非尼在难治性BRAFV600E阳性儿童LCH中似乎安全有效。
  • 需进一步研究寻找有效的维持治疗策略。

研究设计与样本

  • 维莫非尼剂量为20 mg/kg/d。
  • 按风险器官受累(肝、脾和/或血细胞减少)分类:44例阳性,10例阴性。
  • 诊断时中位年龄0.9岁(范围0.1至6.5岁),维莫非尼启动时中位年龄1.8岁(范围0.18至14岁)。
  • 中位随访22个月(范围4.3至57个月),中位治疗持续时间13.9个月(共855患者月)。

主要发现

  • 8周时38例完全缓解、16例部分缓解。
  • 疾病活动评分中位数从诊断时7降至0(P < .001)。
  • 皮肤皮疹最常见不良事件,影响74%患者。
  • 未观察到继发皮肤癌。
  • 30例停药后24例LCH复发。

关键数值与推荐

  • 主要评估标准为不良事件(CTCAE v4.3)和根据疾病活动评分的治疗反应。
  • 治疗血浆维莫非尼浓度范围10至20 mg/L似乎安全有效。
  • 各种经验性维持治疗(造血干细胞移植、克拉屈滨和阿糖胞苷、抗MEK药物、长春碱等)均不能清除BRAFV600E克隆。

临床怎么用

  • 维莫非尼可用于难治性BRAFV600E阳性儿童LCH的治疗。
  • 治疗期间需监测不良事件,尤其是皮肤皮疹。
  • 停药后需警惕复发,BRAFV600E等位基因负荷可能有助于识别高复发风险患者。

局限性

  • 为观察性研究,非随机对照设计。
  • 维持治疗策略尚未明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score. RESULTS: LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to 0 (P < .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) and was associated with a higher risk of reactivation at VMF discontinuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone. CONCLUSION: VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH. Additional studies are needed to find effective maintenance therapy approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019. PMID: 31513482. doi:10.1200/JCO.19.00456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。